Palisade bio's lead product candidate, pali-2108 demonstrates local bioactivation and dose dependent efficacy response in preclinical mouse models

Data presented at digestive disease week (ddw) 2024 preclinical data demonstrate pali-2108 to be safe, effective, and well tolerated pali-2108 is orally delivered and colon-specific allowing for local activity with low systemic exposure pali-2108 exhibited a dose-dependent efficacy response in two dss colitis mouse models, achieving efficacy comparable to doses of apremilast considered intolerable for human use in ulcerative colitis (uc) patients company on track to commence phase 1 human clinical study of lead product candidate, pali-2108, for the treatment of uc before year end carlsbad, ca, may 21, 2024 (globe newswire) -- palisade bio, inc. (nasdaq: pali) (“palisade” or the “company”), biopharmaceutical company focused on developing and advancing novel therapeutics for patients living with autoimmune, inflammatory, and fibrotic diseases, today announced the presentation of positive preclinical data from pali-2108, an orally administered, locally acting colon-specific phosphodiesterase-4 (pde4) inhibitor prodrug in development for patients affected by uc, at ddw 2024 being held in washington, d.c., may 18-21, 2024.
PALI Ratings Summary
PALI Quant Ranking